Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2017

View Archived Issues

Bristol-Myers Squibb initiates phase I trial of BMS-986235 in healthy subjects

Roche opens enrollment in phase III trial of polatuzumab vedotin with R-CHP for DLBCL

Akesobio studies AK-104 in advanced solid tumors

Regeneron initiates phase II study of REGN-2477 for fibrodysplasia ossificans progressiva

Phase II/III data presented for fexinidazole in African T. brucei gambiense trypanosomiasis

Patient enrollment ongoing in phase III study of HD-201 in patients with HER2+ early breast cancer

Servier Canada enters a new partnership with CQDM

Theralase reports on new anticancer vaccine

Initiation of phase I/II study of IMM-529 in patients with Clostridium difficile infection

First preclinical data presented for AG-10 in ATTR cardiomyopathy

Etanercept biosimilar LBEC-0101 demonstrates equivalence to original

Antimalarial SJ-733 safe in first-in-human study

New PROFYLE program in Canada aims to accelerate research breakthroughs in pediatric cancer

Imugene raises financing to advance HER-Vaxx development

Crown Bioscience and DSI collaborate on implantable device to monitor blood glucose in research

INHALE study of Amikacin Inhale does not meet primary endpoint

Alzinova advances preclinical work on ALZ-101

ChAd3-EBO-Z Ebola vaccine well tolerated and immunogenic in children

Puma Biotechnology and Specialised Therapeutics Asia sign commercialization agreement for Nerlynx

Esteve describes novel dual voltage-gated calcium channel ligands and NET inhibitors

New phase I trial explores use of AZD-1775 in head and neck cancer

New proteinase-activated PAR2 receptor antagonists identified at AstraZeneca

Boehringer Ingelheim patents semicarbazide-sensitive amine oxidase inhibitors

AstraZeneca presents novel ataxia telangiectasia mutated kinase inhibitors

Arvinas and Macroceutics establish multi-target screening collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...